Compare Novartis AG (NVS) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Novartis AG trades at $152.33 (market cap $295.37B), while YieldMax TSLA Option Income Strategy ETF trades at $21.94. The key difference: Novartis AG pays a 3.07% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVS | TSLY | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $48.25 |
52-Week Low | $119.31 | $20.49 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TSLY trades at $21.55, up 1.03% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF maintains a high dividend yield strategy, with recent weekly distributions averaging around $0.28 per share. Support and resistance levels are tightly clustered near the current price, indicating limited near-term price movement potential.
The outlook for TSLY is cautious due to capped upside from its option income structure and dependence on Tesla's volatility. Risks include missed participation in Tesla rallies and high distribution volatility. Analyst sentiment has shifted to neutral, reflecting concerns over sustainable yield and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
